SUN.NS
Latest Trade
838.50INRChange
--(--)Today's Range
-
--52 Week Range
-
871.00As of on the National Stock Exchange of India ∙ Minimum 15 minute delay
Previous Close | 838.50 |
|---|---|
Open | -- |
Volume | -- |
3M AVG Volume | 80.97 |
Today's High | -- |
Today's Low | -- |
52 Week High | 871.00 |
52 Week Low | 550.40 |
Shares Out (MIL) | 2,399.33 |
Market Cap (MIL) | 2,031,517.00 |
Forward P/E | 27.97 |
Dividend (Yield %) | 0.89 |
Sun Pharma Says Its Unit DUSA Pharmaceuticals Reached Settlement With Biofrontera
Sun Pharma Says Unit Recalled 69,336 Blister Packs Of Loratadine From U.S. Market
Sun Pharma's U.S.-Based Units Sign Settlement Agreements In Generic Pharmaceuticals Pricing Antitrust Litigation
Sun Pharmaceutical Industries Limited is a pharmaceuticals company. The Company's business segments include US Business, Indian Branded Generics Business, Emerging Markets, Global Consumer Healthcare Business and Active Pharmaceutical Ingredients (API). Its Rest of World segment includes Western Europe, Canada, Australia, New Zealand and other markets. The Company offers its products to therapy areas, such as cardiology, neuro-psychiatry, gastroenterology, anti-infective, diabetology and dermatology. The Company's products include AB PHYLLINE, ABZORB DUSTING POWDER, ACAMPROL, ACOSTIN 3 MIU, ACOSTIN FORTE and AB PHYLLINE SR 200. Its manufacturing units are situated in India, the United States and Brazil, among others. Its units produce generics, branded generics, specialty products, over-the-counter (OTC) products, anti-retroviral (ARVs) and APIs. They also produce intermediates in a range of dosage forms, including tablets, capsules, injectables, ointments, creams and liquids.
Industry
Biotechnology & Drugs
Contact Info
Sun House, CTS No. 201 B/1,, Western Exp
400063
India
+91.22.43244324
http://www.sunpharma.com/Executive Leadership
Israel Makov
Non-Executive Chairman of the Board
C. S. Muralidharan
Chief Financial Officer
Uday Baldota
Chief Executive Officer - Taro Pharmaceutical Industries Limited
Abhay Gandhi
Chief Executive Officer, North America
Kirti Ganorkar
Chief Executive Officer - India Business
Price To Earnings (TTM) | 32.64 |
|---|---|
Price To Sales (TTM) | 5.53 |
Price To Book (MRQ) | 4.10 |
Price To Cash Flow (TTM) | 24.24 |
Total Debt To Equity (MRQ) | 10.61 |
LT Debt To Equity (MRQ) | 1.31 |
Return on Investment (TTM) | 12.59 |
Return on Equity (TTM) | 9.16 |
Indian shares reversed course to fall slightly on Tuesday as pharmaceutical stocks lost their footing on the back of a slide in heavyweight Sun Pharma ahead of its quarterly earnings results later in the day.
Indian shares ended with gains on Wednesday as a tightening U.S. presidential election boosted the dollar and helped buoy domestic IT shares, with Reliance Industries and pharma stocks also providing support.
India's Sun Pharmaceutical Industries Ltd said on Tuesday it would soon begin selling its version of favipiravir, becoming the latest generic drugmaker to supply the antiviral to treat COVID-19 in the world's third worst-hit nation.
* UNIT GETS JAPAN MHLW APPROVAL OF ILUMYA FOR TREATMENT OF PLAQUE PSORIASIS Source text for Eikon: Further company coverage:
* SUN PHARMA AND HIKMA ENTER INTO EXCLUSIVE LICENSING AGREEMENT FOR ILUMYA FOR MIDDLE EAST & NORTH AFRICA REGIONS
Indian drugmaker Sun Pharmaceutical Industries Ltd said on Friday it was testing a plant-derived drug, AQCH, for the potential treatment of COVID-19 as part of a mid-stage trial, with results expected by October.
* RECEIVES APPROVAL FROM DCGI TO INITIATE CLINICAL TRIAL WITH NAFAMOSTAT IN COVID-19 PATIENTS Source text for Eikon: Further company coverage:
Drugmaker Sun Pharmaceutical Industries Ltd said on Friday it has received Indian regulatory approval to start clinical trials of a pancreatitis drug in COVID-19 patients.
Drugmaker Sun Pharmaceutical Industries Ltd said on Friday that it received Indian regulatory approval to start clinical trials of pancreatitis drug nafamostat mesilate in COVID-19 patients.
* SUN PHARMACEUTICAL INDUSTRIES LTD - SPARC AND SUN PHARMA ENTER INTO A WORLDWIDE LICENSE AGREEMENT FOR SCD-044
* MARCH-QUARTER CONSOL NET PAT 4 BILLION RUPEES VERSUS PROFIT OF 6.36 BILLION RUPEES YEAR AGO
* SUN PHARMACEUTICAL SAYS RECEIVED COMMUNICATION FROM USFDA INDICATING THAT HALOL FACILITY HAS BEEN CLASSIFIED AS “OFFICIAL ACTION INDICATED”
Sun Pharmaceutical Industries Ltd's U.S. subsidiary said on Friday it had donated 2.5 million hydroxychloroquine sulfate tablets as a potential treatment for the rapidly spreading coronavirus.
A subsidiary of India's Sun Pharmaceutical Industries Ltd said on Friday it had donated 2.5 million hydroxychloroquine sulfate tablets in the United States as a potential treatment for coronavirus.
* TO BUY-BACK SHARES AT A MAXIMUM PRICE OF 425 RUPEES PER SHARE
* TO CONSIDER SHARE BUYBACK ON MARCH 17 - STATEMENT Further company coverage: (Reporting by Aftab Ahmed)
* SHORTAGE OF PINDOLOL IS DUE TO UNAVAILABILITY OF API SUPPLIES; CO DOESN’T SOURCE API OF PINDOLOL FROM CHINA - SUN PHARMA STATEMENT Further company coverage:
Indian drugmaker Sun Pharmaceutical Industries Ltd reported a shortage of its generic version of hypertension drug pindolol in the United States due to a lack of pharmaceutical ingredients, but said the shortfall did not stem from China.
Indian drugmaker Sun Pharmaceutical Industries Ltd said on Monday there was a shortage of its generic version of hypertension drug pindolol due to unavailability of supply of the drug's ingredients.
* LABEL FOR RIOMET ER CARRIES BOXED WARNING ABOUT RISK OF LACTIC ACIDOSIS WITH EXCESSIVE ALCOHOL INTAKE Source text: (http://bit.ly/2wGSrZ0) Further company coverage:
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.